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Summary 06-alkylguanine-DNA-alkyltransferase (ATase) levels were measured in extracts of peripheral
blood lymphocytes taken at various times during chemotherapy from 19 patients with various haematological
malignancies. Seven patients with advanced Hodgkin's disease received preparative treatment consisting of
cyclophosphamide (1.5 g m-2, daily) administered on days 1 to 4 and BCNU (600 mg m-2) on day 5 prior to
autologous bone marrow rescue (ABMR) delivered on day 7. Treatment in the remaining 12 patients consisted
of cyclophosphamide (1.8 g m2, daily) given on days 1 and 2 followed at day 4 with total body irradiation
(TBI) administered in six fractions over the subsequent 3 days to a total dose of 1200 cGy prior to bone
marrow transplantation. In the Hodgkin's group, significant decreases in ATase activity were seen during the
cyclophosphamide treatment, and the median ATase nadir was 32% (range 0% to 57%) of pretreatment levels
following 4 days of cyclophosphamide. In one patient, no ATase activity was detectable following the 4th
cyclophosphamide treatment. ATase activities decreased further after BCNU administration to a median of
19% (range 0% to 32%) of pretreatment levels. Extensive cyclophosphamide-induced reduction of lymphocyte
ATase levels was also seen in the other group of 12 patients treated with cyclophosphamide/TBI: post-
cyclophosphamide median ATase nadir was 35% (range 12% to 78%) of the pretreatment levels. No ATase
depletion was seen when cyclophosphamide (up to 1OmM) was incubated for 2 h with pure recombinant
human ATase in vitro whereas ATase activity was reduced by 90% on preincubation with 100 tsm acrolein or
with > 1 mM phosphoramide mustard. This suggests that a cyclophosphamide-induced decrease in ATase
levels in human peripheral lymphocytes in vivo may be due to depletion mediated by the production of
intracellular acrolein. Since ATase appears to be a principal mechanism in cellular resistance to the cytotoxic
effects of BCNU and related alkylating agents, these observations suggest that a cyclophosphamide-induced
reduction in ATase activity may be an additional factor in the effectiveness of the combined sequential
therapy.
Autologous Bone Marrow Rescue (ABMR) following ablative
chemotherapy is being increasingly adopted for patients with
high risk advanced Hodgkin's disease, who fail to obtain
complete remission following primary induction chemo-
therapy, relapse within 1 year ofcompleting chemotherapy or
who are in second or subsequent relapse after receiving two
or more standard chemotherapy regimens (Armitage et al.,
1989). Clinical results from recent ABMR series indicate that
despite achieving an initial high response rate (range
70-85%), long term cure is achieved in only about 30-35%
with most relapse occurring at sites previously involved with
disease (Ahmed et al., 1989; Bierman et al., 1988; Carella et
al., 1988; Gribben et al., 1989). This indicates that inade-
quate chemotherapy is the prime reason for failure.
The most popular preparative treatment regimen used for
ABMR in Hodgkin's disease involves carmustine (BCNU) in
combination with cyclophosphamide and etoposide. This was
originally developed by the MD Anderson group (Jagannath
et al., 1986; Spitzer et al., 1980) and several variants are
currently in use (Ahmed et al., 1989; Bierman et al., 1988;
Carella et al., 1988; Gingrich et al., 1990; Gribben et al.,
1989; Reece et al., 1991; Teillet et al., 1987). The mechanism
of cell kiling by BCNU is initiated by the formation of the
mono-adduct, 06-chloroethylguanine which undergoes an
intramolecular rearrangement to form 06, NI-ethanoguanine.
This then reacts with a cytosine residue in the opposite
strand to form a lethal N1-guanine-N3-cytosine ethano DNA
cross-link (Brent, 1985; D'Incalci et al., 1988; Gonzaga et al.,
1990; Pegg, 1990; Tong et al., 1982). The principal mechan-
ism of BCNU resistance involves the DNA repair enzyme,
ATase (Pegg, 1990; D'Incalci et al., 1988) which can remove
the chloroethyl group from 06-chloroethylguanine and hence
prevent the formation of DNA interstrand cross-links. How-
ever, many tumour cells and most tumour cell lines isolated
so far have high ATase levels limiting the potential usefulness
of BCNU (D'Incalci et al., 1988). One theoretical approach
to increasing sensitivity to BCNU is to reduce the levels of
ATase prior to administration of the choroethylating agents.
This can be achieved in the case of ATase because of its
autoinactivating stoichiometric reaction mechanism and its
slow rate of resynthesis (Pegg, 1990). Indeed it has been
shown in cultured cells that depletion of endogenous ATase
by prior exposure to non-toxic doses of monofunctional
methylating agents (Futscher et al., 1989; Zlotogorski &
Erickson, 1984) or 06-methylguanine (Dolan et al., 1985;
Gerson et al., 1988a; Yarosh et al., 1986) or 06-benzyl-
guanine (Dolan et al., 1990) rendered the cells more sensitive
to subsequent treatment with chloroethylating agents. Con-
versely, transfer and expression of ATase genes in ATase
deficient cells renders them more resistant to chloroethylating
agents (Brennand & Margison, 1986; Margison & O'Connor,
1990).
Based on our recent observations of progressive depletion
of ATase activity in human peripheral blood lymphocytes of
patients with malignant melanoma treated with sequential
dacarbazine and fotemustine (Lee et al., 1991a), we began to
examine the kinetics of ATase depletion following BCNU
prior to ABMR. However, results in the first patient to
receive sequential cyclophosphamide and BCNU showed an
unexpected decrease in ATase activity in the post-cyclo-
phosphamide samples. This observation was pursued and we
report here a marked decrease in ATase activity following
cyclophosphamide treatment in seven patients with advanced
Hodgkin's disease receiving cyclophosphamide and BCNU
and in a further group of 12 patients with various haema-
tological malignancies undergoing preparative treatment with
cyclophosphamide and total body irradiation (TBI).
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Materials and methods
Chemicals
Cyclophosphamide was obtained from Farmitalia Carlo Erba
Ltd; acrolein and glutathione were from Sigma Chemical Co
Ltd. and phosphoramide mustard was a generous gift from
Dr A. McGown (Paterson Institute, Manchester, UK).
Freshly prepared stock solutions (100 mM) in distilled water
were used to examine the effects on ATase as described
below.
Patients and bloodsamples
The clinical characteristics of the 19 patients with various
haematological malignancies studied are outlined in Table I.
All the patients with Hodgkin's disease had failed front line
chemotherapy (including MOPP: mechlorethamine, vincris-
tine, procarbazine and prednisolone; ChlVPP: Chlorambucil,
vinblastine, procarbazine and prednisolone or HYBRID:
Vinblastine, procarbazine, prednisolone, chlorambucil, vin-
cristine, etoposide and adriamycin) and/or salvage chemo-
therapy (including VAPEC-B: Adramycin, cyclophosphamide,
vincristine, bleomycin, etoposide and prednisolone or HYB-
RID) or had relapsed less than 12 months after chemo-
therapy. They received preparative treatment consisting of
cyclophosphamide (1.5 g m-2 i.v., daily) administered on
days 1 to 4, BCNU (600 mgm-2 i.v.) on day 5 and autolo-
gous bone marrow rescue on day 7. The remaining 12
patients (Table I) presented with a variety of haematological
diseases and were treated with cyclophosphamide/TBI in
which cyclophosphamide (1.8 g m2 i.v., daily) was given on
day 1 and 2 followed by six fractionated doses of total body
irradiation (200 cGy twice daily) to a total dose of 1,200 cGy
from day 4 to 6 prior to allogeneic or autograft marrow
transplantation. Patients with acute myeloid leukaemia had
previously received combination chemotherapy comprising
cytosine arabinoside, daunorubicin and thioguanine and
patients with acute lymphoblastic leukaemia had combina-
tion chemotherapy with vincristine, daunorubicin, predni-
solone, high dose methotrexate followed by intensification
with vindesine, asparaginase, cytosine arabinoside, predni-
solone and oral maintenance with 6-mercaptopurine and
methotrexate. Patients with chronic myeloid leukaemia had
previously received hydroxyurea treatment. Serial blood sam-
ples were collected at various times during the two preparative
regimens. For the cyclophosphamide/BCNU group, blood
Table I Patients characteristics
ATase activity
(fmmg-')
Patient Age/sex Disease Treatment Initial Nadir
ST 17/F HD IVB Cyclo/BCNU 33 BDa
SH 20/M HD IVB Cyclo/BCNU 148 47
MR 50/F HD IVB Cyclo/BCNU 130 25
MS 23/M HD IVB Cyclo/BCNU 170 55
RD 21/M HD IVB Cyclo/BCNU 162 12
SJ 34/M HD IVB Cyclo/BCNU 163 53
JC 39/F HD IVB Cyclo/BCNU 183 34
AW 26/M AML 1 CR Cyclo/TBI 107 19
GD 45/F AML 1° CR Cyclo/TBI 168 10
LW 36/F AML 1 CR Cyclo/TBI 101 13
DH 43/M AML 1 CR Cyclo/TBI 405 138
SA 44/F ALL 1 CR Cyclo/TBI 461 95
MC 18/F ALL 1° CR Cyclo/TBI 148 18
HR 30/F ALL 1° CR Cyclo/TBI 103 19
TC 21/F ALL 3 CR Cyclo/TBI 168 37
SK 28/F CML 1° CP Cyclo/TBI 160 23
LB 38/M CML I' CP Cyclo/TBI 102 45
CN 38/F CML 1° CP Cyclo/TBI 200 18
RB 54/M NHL 1° PR Cyclo/TBI 107 12
HD: Hodgkin's disease; AML: acutemyeloid leukaemia; ALL: acute
lymphoblastic leukaemia; CML: chronic myeloid leukaemia; NHL:
non-Hodgkin's lymphoma; CR: complete remission; IVB: stage IVB
disease; PR: partial remission; CP: chronic phase; 1°: first; 3: third.
BDa = below detection.
samples were taken just before chemotherapy and approxim-
ately 3, 18, 24, 36, 45, 63, 75, 85, 98, 108, 124 and 132 h after
administration of the first dose ofcyclophosphamide. For the
cyclophosphamide/TBI group, blood samples were taken
before and approximately 3, 6, 15, 22, 29, 50,64, 70, 88, 94,
112, 120 h after chemotherapy. Bloods were drawn into a
20 ml universal container containing 0.5 ml of 0.5% EDTA
and stored at 4°C before isolation of lymphocytes.
06-Alkylguanine-DNA alkyltransferase assay
Lymphocytes (mononuclear cell fraction) were isolated by
centrifugation on Ficoll (Pharmacia, Uppsala, Sweden),
washed with PBS and centrifuged again into a pellet and
stored at - 20°C. The ATase extraction and assay procedure
was carried out as described previously (Lee et al., 1991a)
with slight modifications. Briefly, cells were disrupted by
sonication in 1 ml of buffer I (50 mM Tris-HCI, 3 mM
dithiothreitol, 1 mM EDTA, pH 8.3) and centrifuged to pre-
pare cell extracts. Varying amounts of cell extract were
incubated with 3H-methylnitrosourea-methylated calf thymus
substrate DNA (specific activity, 19 Cimmol-') at 37°C for
2 h in a total volume of 500 tlI of 1 mg ml-' bovine serum
albumin in buffer I. After incubation, bovine serum albumin
(100 tlI of a 10 mgml-' solution in buffer I) and perchloric
acid (200glI of a 4 M solution) were added in rapid succes-
sion. A further 2 ml of 1 M perchloric acid was added and
the mixture heated at 75°C for 45 min. Samples were clarified
by centrifugation and the precipitates were washed with 4 ml
of 1 M perchloric acid before being resuspended in 300 ild of
0.01 M sodium hydroxide and dissolved in 3 ml of aqueous
scintillation fluid (Ecoscint A; National Diagnostics). Count-
ing efficiency was approximately 28%. Specific activity
measurements were based on a minimum of three points on
the linear part of the curve. ATase activity was expressed as
fmoles methyl transferred to protein per mg of total protein
in the extract, protein concentration being measured using
the Bradford method with bovine serum albumin as the
standard (Bradford, 1976). Statistical analysis was based on
repeated measurement analysis using the BMDP statistical
software program and was done on the pre-chemotherapy
and pre-TBI assays.
In order to assess the ability ofcyclophosphamide, acrolein
and phosphoramide mustard to inhibit the ATase in vitro,
varying concentrations of these agents were incubated with
70 fmoles of pure recombinant human ATase (Santibanez-
Koref et al., 1992 in press) for 2 h at 37°C in buffer I without
dithiothreitol. Residual ATase activity was then measured by
incubation with excess substrate DNA. The effect of gluta-
thione on the inhibition of ATase by acrolein was monitored
by incubating various amounts of gluthathione for 2 h with
500M acrolein, a concentration that caused a 95% depletion
in ATase activity in vitro. Following this, 70 fmoles of recom-
binant ATase was added and the experiment continued as
above.
Results
Decrease in ATase in vivofollowing cyclophosphamide and
BCNU
Pretreatment ATase levels in the seven Hodgkin's patients
ranged from 33 to 183 (mean 141) fm mg- total protein. In
all seven patients, decreases in ATase activity were seen
following cyclophosphamide administration. Wide variations
were noted in the rates and extents of ATase reduction
between various individuals (see Figures la and lb). In three
patients the first cyclophosphamide treatment caused reduc-
tion to 52%, 64% and 67% of their pretreatment levels
(patients RD, SH and ST, Figures la and Ib) while in two
other patients the first treatment caused only a 10% loss in
activity (patients SJ and JC, Figure lb). Following four cyclo-
phosphamide treatments the median ATase nadir was 32%
(range 0% to 57%) of pretreatment levels. In one patient (ST,CYCLOPHOSPHAMIDE DECREASES ATase IN HUMAN LYMPHOCYTES 333
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Figure 1 06-alkylguanine-DNA-alkyltransferase (ATase) specific
activity (fmoles mg- protein) in extracts of peripheral lympho-
cytes of Hodgkin's patients sampled at various times after high
dose cyclophosphamide given on day 1, 2, 3 and 4 and BCNU
given on day 5. a, Patients ST (A), SH (A), MR (0) and MS
(0). b, Patients RD (A), SJ (A) and JC (0).
Figure la), no ATase activity was detectable after the fourth
cyclophosphamide treatment. In two patients there was evi-
dence of partial regeneration of ATase during the cyclophos-
phamide treatments (SH and SJ, Figures la and lb). ATase
activities continued to decrease after BCNU administration to
a median of 19% (range 0% to 32%) of pretreatment levels.
Although in some case, the loss of ATase was small after
administration of BCNU; overall there was a substantial
post-BCNU decrease in ATase and this was highly statis-
tically significant: maximal loss occurred between the second
and fourth dose of cyclophosphamide (P = 0.0013) and after
BCNU administration (P = 0.0018). A consensus summary
of the data from all seven patients is shown in Figure 3a.
Decrease in ATase in vivofollowing cyclophosphamide and TBI
Pretreatment ATase levels in the 12 patients monitored
ranged from 101 to 462 (mean 186) fmmg'1. As above, the
extents and rates of decrease in activity were variable with a
median post-cyclophosphamide nadir of 35% (range 12% to
78%) of pretreatment levels. The extent of ATase loss did
not appear to be related to the pretreatment levels. In seven
patients there was a transient increase in ATase activity after
the first dose of cyclophosphamide (SA, MR, HR, TC, LB,
RB and CN, Figures 2b and 2c) followed by reduction to
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Figure 3 Consensus data for 06-alkylguanine-DNA-alkyltrans-
ferase (ATase) specific activity (fmolesmg-I protein) in extracts
of peripheral lymphocytes of a, patients treated with cyclophos-
phamide and BCNU (see Figure 1) and b, patients treated with
cyclophosphamide and TBI (see Figure 2). Figures show mean
values (0) and upper (V) and lower (A) 95% confidence inter-
vals.
nadirs from 80% to 10% of pre-cyclophosphamide levels. In
two patients significant partial recovery of ATase was seen
during the cyclophosphamide treatments and prior to TBI (RB
and SK, Figure 2c). Generally, relatively small changes in
ATase activity were seen during the TBI treatments. However,
in three patients TBI itself appeared to extensively suppress
ATase activity (RB, TC and CN, Figures 2b and 2c) but in
two of these (TC and CN, Figures 2b and 2c) an initial mark-
ed suppression was followed by an equally extensive recovery.
Statistical analysis again showed that the effect of cyclo-
phosphamide on ATase was cumulative, particularly between
the first dose of cyclophosphamide and the second day of
TBI (P<0.0001). A consensus summary of the data from all
12 patients is shown in Figure 3b. Although the mean pre-
treatment ATase activity was higher and the ATase reduction
rate appears faster than in the Hodgkin's group, this was not
statistically significant (P = 0.097 and P = 0.89 respectively)
and there was therefore no correlation between pretreatment
history and ATase loss. The apparently greater individual
variation in ATase in the cyclophosphamide/TBI than the
cyclophosphamide/BCNU group might be related to the fact
that the former group received two and the latter four con-
secutive days of cyclophosphamide treatment, or to the
different pretreatment history.
There was progressive reduction in WBC counts over the
5-7 days of cyclophosphamide/BCNU and cyclophospha-
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Figure 2 06-alkylguanine-DNA-alkyltransferase (ATase) specific activity (fmoles mg-' protein) in extracts of peripheral lympho-
cytes of patients sampled at various times after cyclophosphamide given on day and 2 and TBI given on days 4, 5 and 6. a,
Patients AW (A), GD (A), CW (0) and DH (0). b, Patients SA (A), MR (A), HR (0) and TC (0). c, Patients SK (A), LB
(A), CN (0) and RB (0).
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Figure 4 a, Effect of pre-incubation of pure recombinant human
06-alkylguanine-DNA-alkyltransferase (ATase) with increasing
concentrations of cyclophosphamide (0), phosphoramide mus-
tard (0) or acrolein (0). See text for experimental details. b
Effect of preincubation of acrolein with increasing concentrations
of glutathione (GSH) on its ability to deplete the activity of pure
recombinant human ATase.
mide/TBI: the mean pretreatment leucocyte count was
7.04 x 109 1- and mean post-cyclophosphamide leucocyte
count was 3.18 x 09 1-'.
ATase depletion in vitrofollowing incubation with
cyclophosphamide and its metabolites
The direct effects of cyclophosphamide, acrolein and phos-
phoramide mustard on ATase were also assessed by incub-
ating the drugs with a fixed amount of pure recombinant
human ATase for 2 h at 37°C in vitro. Figure 4a shows the
dose-response curves for ATase depletion following incuba-
tion with the above drugs. No ATase depletion was seen
when recombinant human ATase was incubated with cyclo-
phosphamide. By contrast, acrolein was a highly effective
inactivator of the enzyme, in that under the conditions used,
only 100 jLM caused 90% depletion. ATase depletion was also
seen with phosphoramide mustard but this was with a con-
centration far in excess of that achievable in patients receiv-
ing the drug (>1 mM) (Jardine et al., 1978; Sladek et al.,
1984; Juma et al., 1979).
Increasing concentrations of glutathione were also incub-
ated with 500 SM acrolein which caused 95% depletion of
ATase activity in the competition assay above. As shown in
Figure 4b, 1 mM glutathione was able to completely prevent
acrolein-induced depletion of ATase.
Discussion
In the present study we have shown extensive decreases in
ATase activity in peripheral blood lymphocytes of 19 patients
receiving cyclophosphamide preparative treatment prior to
bone marrOw transplantation. Wide interindividual variations
in the pretreatment levels and in the rate of ATase loss was
noted. In the Hodgkin's patients the effect was so marked
that after the 4th cyclophosphamide treatment the median
ATase nadir was 32% (range 0 to 57%). In one patient
(Figure la) no ATase activity was detected following the 4th
cyclophosphamide administration. The two patients that
showed least overall decrease immediately prior to BCNU
demonstrated partial recovery of ATase activity during the
cyclophosphamide treatments and this may have contributed
to the overall lower ATase reduction (Figures la and lb).
Although in some cases, the loss of ATase was minor after
administration of BCNU, overall there was a substantial
decrease in ATase and this was highly statistically significant
with maximal loss occuring between the second and fourth
dose of cyclophosphamide (P= 0.0013) and after BCNU
administration (P= 0.0018) (Figure 3a). The significant
reduction of ATase observed, agrees with that of another
study (Gerson, 1989) using 350mgm2 of BCNU.
A similar picture emerged in the other group of 12 patients
treated with cyclophosphamide/TBI, with a median post-
cyclophosphamide nadir of 39%. In two patients partial
recovery of ATase was seen during the cyclophosphamide
treatments and prior to TBI (Figures 2b and 2c). In two
patients there was some indication that TBI itself was associ-
ated with a transient (Figures 2b and 2c), and in one patient,
continued (Figure 2c) suppression of ATase activity. Clearly
this effect requires substantiation with a large number of
patients receiving only TBI. It is interesting to note that in
rodents, ATase activity in a number of tissues was increased
by a single dose of ionising radiation (Margison et al., 1985;
Stammberger et al., 1990).
Changes in the specific activity of peripheral lymphocyte
ATase might be the consequence of cyclophosphamide-induc-
ed changes in the lymphocyte population: transient increases
in ATase activity were seen in some patients but the changes
were slight and may have been due to experimental variation
or intra-individual variation. However, in the latter case it
has been shown that most individuals have characteristic
lymphocyte ATase levels over a short term period and this is
therefore unlikely to contribute to the overall picture (Gerson
et al., 1985; Sagher et al., 1988). It is also possible that clonal
selection may have occurred as a consequence of cytolysis of
a lymphocyte population(s) with relatively low ATase specific
activity. The possibility that continued cytolysis may have
contributed to the consistent decrease in ATase by affecting
those lymphocytes with the highest specific activity cannot be
excluded since white cell counts had decreased by approx-
imately 50% post cyclophosphamide. Whilst the relative con-
tribution of T and B lymphocytes to the overall ATase
measurements was not assessed in this study, previous
reports have shown ATase specific activities of 190 and
140 fm mg' respectively (Gerson et al., 1985). However, the
overall changes we have observed are unlikely to be attri-
butable to T or B specific effects since B lymphocytes make
up only a small proportion of the total population and the
proportion of T and B cells is similar in Hodgkin's, non-
Hodgkin's lymphoma and controls (Herrmann et al., 1983).
Another possible explanation for ATase loss is that there is
a direct depleting effect on the ATase itself: as far as we are
aware, 06-alkylguanine lesions have not yet been identified in
DNA in vivo after administration of cyclophosphamide or its
metabolites. There are two reports (Kleihues & Margison,
1976; Meer et al., 1989) which showed that cyclophospha-
mide is able to increase the amount of 06-methylguanine in
DNA following a chasing dose of methylating agent in
rodent liver and both authors attributed this to some as yet
unidentified 06-alkylation product of guanine in DNA which
is repaired by ATase and results in ATase depletion. Alterna-
tively, there may be a direct reaction of the cyclophospha-
mide metabolite acrolein with ATase: when given systemically,
cyclophosphamide is metabolised by the hepatic mixed-
function oxidases, to 4-hydroxycyclophosphamide, the 'trans-
port' form which enters cells and eventually decomposes
intracellularly to phosphoramide mustard, the ultimate cross-
linking metabolite of cyclophosphamide, and acrolein (Brock,
1989; Sladek, 1987). We have shown that 100 LM acrolein isCYCLOPHOSPHAMIDE DECREASES ATase IN HUMAN LYMPHOCYTES 335
able to deplete ATase activity when it was incubated in vitro
with pure recombinant human ATase. This may be the result
of the affinity of acrolein for sulfhydryl groups including,
possibly, the alkyl-accepting cysteine residue of the ATase
protein. The peak concentration of phosphoramide mustard
achieved in the serum following high dose cyclophosphamide
(60 and 75 mg kg-') was 50-100 ILM (Colvin & Chabner,
1990; Jardine et al., 1978; Juma et al., 1979) indicating that
the concentration of intracellular acrolein that depletes re-
combinant human ATase in vitro is potentially attainable in
vivo. Phosphoramide mustard was also able to deplete ATase
activity but the concentration required (>1 mM) was far in
excess of that achievable in patients receiving the drug (Col-
vin & Chabner, 1990; Jardine et al., 1978; Sladek et al.,
1984).
The variation in ATase decreases seen in the 19 patients
studies following cyclophosphamide treatment may be due to
the differential metabolism ofcyclophosphamide or related to
variations in cellular glutathione and glutathione transferase
levels in different individuals, as both are responsible for the
intracellular metabolism and detoxification of various cyclo-
phosphamide metabolites (Chresta et al., 1990; Draeger et
al., 1976; Lee, 1991b; McGown & Fox, 1986). It has pre-
viously been demonstrated that the amount of the ultimate
active metabolites formed intracellularly is dependent on the
intracellular glutathione concentration and its interaction
with the toxic metabolites (Lee et al., 1991c). Cyclophos-
phamide has also been shown to be able to deplete serum
glutathione (Carmichael et al., 1986). Here we were able to
show that glutathione can inhibit acrolein-induced depletion
of ATase, supporting the hypothesis that in the case of
lymphocytes, intracellular glutathione levels may be one of
the factors that determines the extent of ATase decrease.
Irrespective of the mechanism, our observations on peri-
pheral lymphocytes may have important general implications
in combination chemotherapy if similar changes in ATase
occur in the tumour and indeed, if the extents of ATase loss
achieved are sufficient to sensitise the tumour cells to killing
by agents such as BCNU. In cultured human tumour cells
lines that express high levels of ATase, depletion of the
enzyme following exposure to 06-benzylguanine increases
their sensitivity to the toxic effects of subsequent doses of
chloroethylating agents, greater extents of sensitisation being
produced in cells expressing higher levels of ATase: no such
sensitisation occurs in equivalent ATase deficient cells (Dolan
et al., 1991). It might therefore be argued that enzyme deple-
tion in ATase-expressing tumour cells would considerably
enhance chemotherapeutic effectiveness without significantly
increasing the toxic side effects in tissues such as bone mar-
row that generally express low levels of the enzyme.
It is not unreasonable to suggest that the ATase-reducing
action of cyclophosphamide would best be exploited by
employing sequential cyclophosphamide and BCNU (as here)
rather than a regimen in which cyclophosphamide and
BCNU are administered concurrently or in which BCNU is
given before cyclophosphamide. Further support for such a
schedule is that intracellularly released acrolein has been
shown to deplete cellular glutathione (Gurtoo et al., 1981;
Lee, 1991b) and the latter is able to decrease the cytotoxic
and DNA cross-linking activity of BCNU (Ali-Osman et al.,
1989). Therefore, if used as in the schedule described here,
the glutathione-depleting property of acrolein may further
sensitise tumour cells to BCNU. In support ofthis suggestion
it is interesting to note that in one series of 54 patients with
advanced Hodgkin's disease undergoing ABMR (Reece et al.,
1991), where the condition schedule involved administering
BCNU after cyclophosphamide together with etoposide, the
complete response rate and disease-free survival rate were
80% and 55% respectively. In contrast, most other series
using similar preparative drugs, but different schedules, the
complete response rate averaged about 45% and only
approximately 10 to 30% achieved disease-free survival
(Ahmed et al., 1989; Bierman et al., 1988; Carella et al.,
1988; Jagannath et al., 1986).
In conclusion, cyclophosphamide is capable of reducing
ATase activity in peripheral lymphocytes and one possible
explanation is that this is mediated via the release ofintracel-
lular acrolein, a cyclophosphamide metabolite. This property
could be exploited in designing future combination chemo-
therapy schedules; this method of reducing cellular ATase
levels may be an alternative to the proposed use of agents
such as 06-benzylguanine since, in the case of cyclophospha-
mide, reduction is accomplished by an agent with proven
antitumour activity.
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Christie Hospital for blood sampling. This work was supported by
funds from the Cancer Research Campaign, UK.
References
AHMED, T., CIAVARELLA, D., FELDMAN, E., ASCENSAO, J., HUS- SAIN, F., ENGELKING, C., GINGRICH, S., MITTELMAN, A., COLEMAN, M. & ARLIN, Z.A. (1989). High-dose potentially mye- loablative chemotherapy and autologous bone marrow transplan- tation for patients with advanced Hodgkin's disease. Leukemia, 3, 19-32.
ALI-OSMAN, F., CAUGHLAN, J. & GRAY, G.S. (1989). Decreased DNA interstrand cross-linking and cytotoxicity induced in human brain tumour cells by 1,3-bis(2-chloroethyl)-1-nitrosourea after in vitro reaction with glutathione. Cancer Res., 49, 5954-5948.
ARMITAGE, J.O., BARNETr, M.J., CARELLA, A.M., DICKE, K.A., DIEHL, V., GRIBBEN, J.G. & PREUNDSCHUH, M. (1989). Bone marrow transplantation in the treatment of Hodgkin's lymph- oma: problems, remaining challenges and future prospects. In New Aspects in Diagnosis and Treatment of Hodgkin's Disease. Diehl, V., Pfreundschuh, M. & Loeffler, M. (eds), pp. 246-253. Springer-Verlag: Berlin-Heidelberg.
BIERMAN, P.J., JAGANNATH, S., DICKE, K.A., KESSINGER, A., HAGERRMEISTER, F.B., VOSE, J.M., HORWITZ, L.J., CABANIL- LAS, F., VAUGHAN, W.P., SPITZER, G. & ARMITAGE, J.O. (1988). High dose cyclophosphamide, carmustine and etoposide (CBV) in 128 patients with Hodgkin's disease. Blood, 72 (suppl 1), 239a. BRADFORD, M.M. (1976). A rapid and sensitive method for the quantitation of microgram quantities of protein utilising the prin- ciple of protein-dye binding. Anal. Biochem., 72, 248-254. BRENNAD, J. & MARGISON, G.P. (1986). Reduction of the toxicity and mutagenicity ofalkylating agents in mammalian cells harbor- ing the Escherichia coli alkyltransferase gene. Proc. Natl Acad. Sci. USA, 83, 6292-6296.
BRENT, T.P. (1985). Isolation and purification of 06-alkylguanine-
DNA alkyltransferase from human leukemic cells: prevention of
chloroethylnitrosourea-induced cross-links by purified enzyme.
Pharmacol. Ther., 31, 121-140.
BROCK, N. (1989). Oxazaphosphorine cytostatics: past-present-
future. Seventh Cain Memorial Award Lecture. Cancer Res., 49,
1-7.
CARELLA, A., CONGIU, A.M., GAOZZA, E., MAZZA, P., RICCI, P.,
VISANI, G., MELANI, G., CIMINO, G., MANGONI, L., COSER, P.,
CETTO, G.L., CIMINO, R., ALESSANDRINO, E.P., BRUSAMOL-
INO, E., SANTINI, G., TURA, S., MANDELLI, F., RIZZOLI, V.,
BERNASCONI, C. & MARMONT, A.M. (1988). High-dose chemo-
therapy with autologous bone marrow transplantation in 50
advanced resistant Hodgkin's disease patients: an Italian group
report. J. Clin. Oncol., 6, 1411-1416.
CARMICHAEL, J., ADAMS, D.J., ANSELL, J. & WOLF, R. (1986).
Glutathione and glutathione transferase levels in mouse granu- locytes following cyclophosphamide administration. Cancer Res.,
46, 735-739.
CHRESTA, C.M., CROOK, T.R. & SOUHAMI, R.L. (1990). Depletion of
cellular glutathione by N,N'-Bis (trans-4-hydrocyclohexyl)-N'-
nitrosourea as a determinant of sensitivity of K562 human leu-
kemia cells to 4-hydroperoxycyclophosphamide. Cancer Res., 50,
4067.
COLVIN, M. & CHABNER, B.A. (1990). Alkylating agents. In Cancer
Chemotherapy: Principles and Practice, Chabner, B.A. & Collins, J.M. (eds), pp. 276-313. Lippincott: Philadelphia.
D'INCALCI, M., CITTI, L., TAVERNA, P. & CATAPANO, C.V. (1988).
Importance of DNA repair enzyme 06-alkyltransferase (AT) in
cancer chemotherapy. Cancer Treat. Rev., 15, 279-292.336 S.M. LEE et al.
DOLAN, M.E., CORSICO, C.D. & PEGG, A.E. (1985). Exposure of
HeLa cells to 06-alkylguanines increases sensitivity to the cyto-
toxic effects of alkylating agents. Biochem. Biophys. Res. Com-
mun., 132, 178-185.
DOLAN, M.E., ROBERT, C.M. & PEGG, A.E. (1990). Depletion of
mammalian 06-alkylguanine-DNA alkyltransferase activity by
06-benzylguanine provides a means to evaluate the role of this
protein in protection against carcinogenic and therapeutic agents.
Proc. Nati Acad. Sci. USA, 87, 5368-5372.
DOLAN, M.E., MITCHELL, R.B., MUMMERT, C., MOSCHEL, R.C. &
PEGG, A.E. (1991). Effects of 06-benzylguanine analogues on
sensitivity of human tumor cells to the cytotoxic effects of alky-
lating agents. Cancer Res., 51, 3367-3372.
DRAEGER, U., PETER, G. & HOHORST, H.J. (1976). Deactivation of
cyclophosphamide (NSC-26271) metabolites by sulphydryl com-
pounds. Cancer Treat. Rep., 60, 355-359.
FUTSCHER, B.W., MICETICH, K.C., BARNES, D.M., FISHER, R.I. &
ERICKSON, L.C. (1989). Inhibition of a specific DNA repair
system and nitrosourea cytotoxicity in resistant human cancer
cells. Cancer Commun., 1, 65-73.
GERSON, S.L., MILLER, K. & BERGER, N.A. (1985). 06-alkylguanine-
DNA alkyltransferase activity in myeloid cells. J. Clin. Invest., 76,
2106-2114.
GERSON, S.L., TREY, J.E. & MILLER, K. (1988). Potentiation of
nitrosourea cytotoxicity in human leukemic cells by inactivation
of 06-alkylguanine-DNA alkyltransferase. Cancer Res., 48, 1521-
1527.
GERSON, S.L. (1989). Modulation of human lymphocyte 06-alkyl-
guanine- DNA alkyltransferase by streptozotocin in vivo. Cancer
Res., 49, 3134-3138.
GINGRICH, R.D., GINDER, G.D., BURNS, L.J., WEN, B.-C. & FYFE,
M.A. (1990). BVAC ablative chemotherapy followed by auto-
logous bone marrow transplantation for patients with advanced
lymphoma. Blood, 75, 2276-2281.
GONZAGA, P.E., HARRIS, L., MARGISON, G.P. & BRENT, T.P. (1990).
Evidence that covalent complex formation between BCNU-treat-
ed oligonucleotides and E. coli alkyltransferases requires the 06-
alkylguanine function. Nucleic Acids Res., 18, 3961-3966.
GRIBBEN, J.G., LINCH, D.C., SINGER, C.R.J., MCMILLAN, A.K., JAR-
RETT, M. & GOLDSTONE, A.H. (1989). Successful treatment of
refractory Hodgkin's disease by high-dose combination chemo-
therapy and autologous bone marrow transplantation. Blood, 73,
340-344.
GURTOO, H.L., HIPKENS, J.H. & SHARMA, S.D. (1981). Role of
glutathione in the metabolism-dependent toxicity and chemo-
therapy of cyclophosphamide. Cancer Res., 41, 3584-3591.
HERRMANN, F., SIEBER, G., JAUER, B., LOCHNER, A., KOMIS-
CHKE, B. & RUHL, H. (1983). Evaluation of the circulating and
splenic lymphocyte subpopulations in patients with non-
Hodgkin's lymphomas and Hodgkin's disease using monoclonal
antibodies. Blut, 47, 41-51.
JAGANNATH, S., DICKE, K.A., ARMITAGE, J.O., CABANILLAS, F.,
HORWITZ, L.J., VELLEKOOP, L., ZANDER, A.R. & SPITZER, G.
(1986). High dose cyclophosphamide, carmustine and etoposide
and autologous bone marrow transplantation for relapsed Hodg-
kin's disease. Ann. Intern. Med., 1024, 4163-4168.
JARDINE, I., FENSELAU, C., APPLER, M., KAN, M-N., BRUNDRETT,
R.B. & COLVIN, M. (1978). Quantitation by gas chromatography-
chemical ionization mass spectrometry of cyclophosphamide,
phosphoramide mustard, and nornitrogen mustard in the plasma
and urine of patients receiving cyclophosphamide therapy. Cancer
Res., 38, 408-415.
JUMA, F.D., ROGERS, H.J. & TROUNCE, J.R. (1979). The pharmaco-
kinetics of cyclophosphamide, phosphoramide mustard and nor-
nitrogen mustard studied by gas chromatography in patients
receiving cyclophosphamide therapy. Br. J. Clin. Pharmacol., 10,
209-217.
KLEIHUES, P. & MARGISON, G.P. (1976). Exhausion and recovery of
repair excision of06-methylguanine from rat liver DNA. Nature,
259, 153-155.
LEE, S.M., THATCHER, N. & MARGISON, G.P. (1991a). 06-alkyl-
guanine-DNA alkyltransferase depletion and regeneration in
human peripheral lymphocytes following dacarbazine and fote-
mustine. Cancer Res., 51, 619-623.
LEE, F.Y.F. (199lb). Glutathione diminishes the anti-tumour activity
of 4-hydroperoxycyclophosphamide by stabilising its spontaneous
breakdown to alylating metabolites. Br. J. Cancer, 63, 45-50.
LEE, F.Y.F., FLANNERY, D.J. & SIEMANN, D.W. (1991c). Prediction
of tumour sensitivity to 4-hydroperoxycyclophosphamide by a
glutathione-targeted assay. Br. J. Cancer, 63, 217-222.
MARGISON, G.P., BUTLER, J. & HOEY, B. (1985). 06-methylguanine
activity is increased in rat tissues by ionising radiation. Car-
cinogenesis, 6, 1699-1702.
MARGISON, G.P. & O'CONNOR, P.J. (1990). Biological consequences
of reactions with DNA: role of specific lesions. In Handbook of
Experimental Pharmacology, Vol 94/I. Cooper, C.S. & Grover,
P.L. (eds), pp. 547-571. Springer-Verlag: Berlin-Heidelberg.
MCGOWN, A.T. & FOX, B.W. (1986). A proposed mechanism of
resistance to cyclophosphamide and phosphoramide mustard in a
Yoshida cell line in vitro. Cancer Chemother. Pharmacol., 17,
223-226.
MEER, L., SCHOLD, S.C. & KLEIHUES, P. (1989). Inhibition of the
hepatic 06-alkylguanine-DNA alkyltransferase in vivo by pretreat-
ment with antineoplastic agents. Biochem. Pharmacol., 38, 929-
934.
PEGG, A.E. (1990). Mammalian 06-alkylguanine-DNA alkyltrans-
ferase: regulation and importance in repsonse to alkylating car-
cinogenic and therapeutic agents. Cancer Res., 50, 6119-6129.
REECE, D.E., BARNETT, M.J., CONNORS, J.M., FAIREY, R.N.,
GREER, J.P., HERZIG, G.P., HERZIG, R.H., KLINGEMANN, H-G.,
O'REILLY, S.E., SHEPHERD, J.D., SPINELLI, J.J., VOSS, N.J.,
WOLFF, S.N. & PHILLIPS, G.L. (1991). Intensive chemotherapy
with cyclophosphamide, carmustine, and etoposide followed by
autologous bone marrow transplantation for relapsed Hodgkin's
disease. J. Clin. Oncol., 9, 1871-1879.
SAGHER, D., KARRISON, T., SCHWARTZ, J.L., LARSON, R., MEIER,
P. & STRAUSS, B. (1988). Low 06-alkylguanine DNA alkyltrans-
ferase activity in the peripheral blood lymphocytes of patients
with therapy-related acute nonlymphocytic leukemia. Cancer
Res., 48, 3084-3089.
SANTIBANEZ-KOREF, M., ELDER, R.H., FAN, C.-Y., CAWKWELL, L.,
MCKIE, J.H., DOUGLAS, K.T., MARGISON, G.P. & RAFFERTY,
J.A. (1992). Isolation and partial characterisation of murine o6_
alkylguanine-DNA-alkyltransferase; comparative sequence and
structural properties. Molecular Carcinogenesis, 5, 161-169.
SLADEK, N.E., DOEDEN, D., POWERS, J.F. & KRIVIT, W. (1984).
Plasma concentrations of 4-hydroxycyclopohosphamide and
phosphoramide mustard in patients repeatedly given high doses
of cyclophosphamide in preparation for bone marrow transplan-
tation. Cancer Treat. Rep., 68, 1247-1254.
SLADEK, N.E. (1987). Oxazaphosphorines. In Metabolism and Action
of Anti-Cancer Drugs, Powis, G. & Prough, R.A. (eds), pp. 48-
90. Taylor and Francis: London.
SPITZER, G., DICKE, K.A., LITAM, J., VERMA, D.S., ZANDER, A.,
LANZOTTI, V., VALDIVIESO, M., MCCREDIE, K.B. & SAMUELS,
M.L. (1980). High dose combination chemotherapy with
autologous bone marrow transplantation in adult solid tumours.
Cancer, 45, 3075-3085.
STAMMBERGER, I., SCHMAHL, W. & NICE, L. (1990). The effects of
x-irradiation, N-ethyl-N-nitrosourea or combined treatment on
06-alkylguanine-DNA alkyltransferase activity in fetal rat brain
and liver and the induction of CNS tumours. Carcinogenesis, 11,
219-222.
TEILLET, F., PULIK, M., TEILLET-THIEBAND, F., BLAISE, A.M.,
KUENTZ, M., COURTOIS, F., ANDOLENKO, P., BLEICHNER, G. &
COSTE, F. (1987). Autologous bone marrow transplantation
(ABMT) in poor prognosis Hodgkin's disease. Bone Marrow
Transplant, 2 (suppl 1), 211.
TONG, W.P., KIRK, M.C. & LUDLUM, D.B. (1982). Formation of the
crosslink 1-[N3-deoxycytidyl],2-[N'-doxyguanosinyl]ethane in
DNA treated with N,N-bis(chloroethyl)-N-nitrosourea. Cancer
Res., 42, 3102-3105.
YAROSH, D.B., HURST-CALDERONE, S., BABICH, M.A. & DAY, R.S.
III (1986). Inactivation of 06-methylguanine-DNA methyltrans-
ferase and sensitization of human tumour cells to killing by
chloroethylnitrosourea by 06-methylguanine as a free base.
Cancer Res., 46, 1663-1668.
ZLOTOGORSKI, C. & ERICKSON, L.C. (1984). Pretreatment of human
colon tumour cells with DNA methylating agents inhibits their
ability to repair chloroethyl monoadducts. Carcinogenesis, 5,
83-87.